Terms: = Breast cancer AND FCGR2B, FCGR2, 2213, ENSG00000072694, CD32, CD32B, P31994, IGFR2, FCG2 AND Prognosis
3 results:
1. Immune characteristics and clinical significance of peripheral blood lymphocytes in breast cancer.
Gao H; Ouyang D; Guan X; Xu J; Chen Q; Zeng L; Pang J; Zou Q; Qian K; Yi W
BMC Cancer; 2024 Jan; 24(1):50. PubMed ID: 38195475
[TBL] [Abstract] [Full Text] [Related]
2. Direct cd32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment.
Sconocchia G; Lanzilli G; Cesarini V; Silvestris DA; Rezvani K; Arriga R; Caratelli S; Chen K; Dou J; Cenciarelli C; Toietta G; Baldari S; Sconocchia T; De Paolis F; Aureli A; Iezzi G; Irno Consalvo M; Buccisano F; Del Principe MI; Maurillo L; Venditti A; Ottaviani A; Spagnoli GC
Life Sci Alliance; 2022 Dec; 5(12):. PubMed ID: 36241426
[TBL] [Abstract] [Full Text] [Related]
3. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic breast cancer.
Cejalvo JM; Martínez de Dueñas E; Galván P; García-Recio S; Burgués Gasión O; Paré L; Antolín S; Martinello R; Blancas I; Adamo B; Guerrero-Zotano Á; Muñoz M; Nucíforo P; Vidal M; Pérez RM; Chacón López-Muniz JI; Caballero R; Peg V; Carrasco E; Rojo F; Perou CM; Cortés J; Adamo V; Albanell J; Gomis RR; Lluch A; Prat A
Cancer Res; 2017 May; 77(9):2213-2221. PubMed ID: 28249905
[TBL] [Abstract] [Full Text] [Related]
